Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84157 | 0.82 | SYK (0.50) | SYKALDH1A1DYRK1AAURKAAURKB | |
| SCHEMBL3265212 | 0.77 | SYK (0.49) | SYKALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL20832707 | 0.76 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTKMT2AKDM4E | |
| SCHEMBL5345094 | 0.73 | NUDT1 (0.30) | — | |
| SCHEMBL4883101 | 0.73 | CCR1 (0.36) | SYKCYP1A2CYP3A4CYP2D6MAPK13 | |
| SCHEMBL2032467 | 0.73 | NUDT1 (0.49) | AURKAROCK1CDK2 | |
| SCHEMBL3265737 | 0.71 | HTR3A (0.39) | SYKALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL750287 | 0.70 | CCNT1 (0.38) | ALDH1A1DYRK1AMAPK9MEN1NPC1 | |
| Bromide SCHEMBL28439102 | 0.69 | HTR3A (0.39) | SYKALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4193836 | 0.69 | LOXL2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809358-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809358-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8778955-B2 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778955-B2 | Indole derivatives or benzimidazole derivatives for modulating IkB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| EP-2233483-B1 | Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation. | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-05-09 | — | — | EP | disclosed |
| EP-1530568-B1 | INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2233483-A1 | Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation. | Sanofi-Aventis Deutschland GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1531819-B1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-12-24 | — | — | EP | disclosed |
| US-7462638-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7285560-B2 | Indole derivatives or benzimidazole derivatives for modulating IκB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-23 | — | — | US | disclosed |
| US-7285560-B2 | Indole derivatives or benzimidazole derivatives for modulating IκB kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-23 | — | — | US | disclosed |
| US-20070244139-A1 | Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244139-A1 | Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-7279575-B2 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2007-10-09 | — | — | US | disclosed |
| US-20070142417-A1 | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | AVENTIS PHARMACEUTICALS INC (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142417-A1 | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | AVENTIS PHARMACEUTICALS INC (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1531819-A1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244139-A1 | Indole Derivatives or Benzimidazole Derivatives for Modulating IkB Kinase | IKBKB, IKBKG, IKBKE | SYK 359/4885ALDH1A1 2897/4885CYP1A2 2436/4885 |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | NFKBIA, IKBKB, IKBKE | SYK 172/4885ALDH1A1 2610/4885CYP1A2 4269/4885 |
| US-20070142417-A1 | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | IKBKB, NFKBIA, IKBKG | SYK 170/4885ALDH1A1 3264/4885CYP1A2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.